Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments

Journal of Viral Hepatitis

Volumn 12, Issue 5, 2005, Pages 543-550

  Sypsa, V ^a   Touloumi, G ^a   Papatheodoridis, G V ^b   Tassopoulos, N C ^c   Ketikoglou, I ^b   Vafiadis, I ^d   Hatzis, G ^d   Tsantoulas, D ^e   Akriviadis, E ^f   Koutsounas, S ^g   Hatzakis, Angelos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c Western Attica General Hospital   (Greece)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e SISMANOGLIO HOSPITAL   (Greece)

^f Aristotle University of Thessaloniki   (Greece)

^g Social Insurance Foundation   (Greece)

Author keywords

Chronic hepatitis C; Fibrosis; Markov modelling; Prediction; Treatment

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; EPIDEMIC; FEMALE; GREECE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FORECASTING; GREECE; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER FAILURE; MODELS, STATISTICAL; PREVALENCE; PROBABILITY;

EID: 24044514974     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00588.x     Document Type: Article

References (48)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): 35-46.
2. WHO. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1999; 49: 425-427.
3. National Institutes of Health Consensus Development Conference Management of hepatitis C: 2002. Hepatology 2002; 36 (Suppl. 1): 3-20.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750.
5. La Vecchia C, Lucchini F, Franceschi S, Negri E, Levi F. Trends in mortality from primary liver cancer in Europe. Eur J Cancer 2000; 36: 909-915.
6. Deuffic S, Buffat L, Poynard T, Valleron AJ. Modeling the hepatitis C virus epidemic in France. Hepatology 1999; 29: 1596-1601.
7. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United states. Am J Public Health 2000; 90: 1562-1569.
8. Zou S, Tepper M, El Saadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterol 2000; 14: 575-580.
9. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777-782.
10. Law MG. Modeling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group. J Gastroenterol Hepatol 1999; 14: 1100-1107.
11. Sagmeister M, Renner EL, Mullhaupt B, Wong JB. Simulation of hepatitis C based on a mandatory reporting system. Eur J Gastroenterol Hepatol 2002; 14: 25-34.
12. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
13. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982.
14. Twombly R. Can increased treatment of hepatitis C stem the tide of liver cancer? J Natl Cancer Inst 2002; 94: 1050-1052.
15. Sypsa V, Touloumi G, Tassopoulos NC et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004; 11: 366-374.
16. Tassopoulos NC, Vafiadis I, Tsantoulas D et al. IFN-alpha2b monotherapy in patients with chronic hepatitis C and persistently normal or near normal aminotransferase activity: a randomized, controlled study. J Interferon Cytokine Res 2002; 22: 365-369.
17. Tassopoulos NC, Ketikoglou I, Tsantoulas D et al. A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naive patients with chronic hepatitis C. J Viral Hepat 2003; 10(5): 383-389.
18. Tassopoulos NC, Tsantoulas D, Raptopoulou M et al. Efficacy of daily interferon-alpha-2b (IFN-α) in combination with ribavirin in the treatment of non-responder patients with chronic hepatitis C (CHC): a randomised controlled trial. J Viral Hepat 2003; 10(3): 189-196.
19. Papatheodoridis GV, Katsoulidou A, Touloumi G, Delladetsima JK, Hatzakis A, Tassopoulos NC. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission. Eur J Gastroenterol Hepatol 1996; 8: 469-475.
20. Tassopoulos NC, Karvountzis G, Touloumi G et al. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial. Am J Gastroenterol 1996; 91: 1734-1738.
21. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
22. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832.
23. Hunink M, Glasziou P, Siegel J et al. Decision Making in Health and Medicine. Cambridge, UK: Cambridge University Press, 2001.
24. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.N Engl J Med 1998; 339: 1485-1492.
25. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
26. Hadziyannis SJ, Cheinquer H, Morgan T. Peginterferon alfa-2a (40 KD) (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36(Suppl. 1): 3.
27. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.
28. Cheng SJ, Bonis PA, Lau J, Pham NQ, Wong JB. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials. Hepatology 2001; 33: 231-240.
29. Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S.
30. Rosenberg PS, Gail MH, Carroll RJ. Estimating HIV prevalence and projecting AIDS incidence in the United States: a model that accounts for therapy and changes in the surveillance definition of AIDS. Stat Med 1992; 11: 1633-1655.
31. Rosenberg PS. Scope of the AIDS epidemic in the United States. Science 1995; 270: 1372-1375.
32. Anderson RM, Donnelly CA, Ferguson NM et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779-788.
33. Seeff LB, Buskell-Bales Z, Wright EC et al. Long-term mortality after transfusion-associated non-A non-B hepatitis. New Engl J Med 1992; 327: 1906-1911.
34. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-1233.
35. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-1695.
36. Seeff LB, Miller RN, Rabkin CS et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 105-111.
37. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001; 33: 455-463.
38. Atenstaedt RL. Hepatitis C surveillance in the West Midlands. Commun Dis Public Health 2002; 5: 257.
39. Davis GL, Rodrigue JR. Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001; 345: 215-217.
40. Edlin BR, Seal KH, Lorvick J et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users? N Engl J Med 2001; 345: 211-215.
41. Stephenson J. Former addicts face barriers to treatment for HCV. JAMA 2001; 285: 1003-1005.
42. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
43. Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356: 291-296.
44. Medley GF, Lindop NA, Edmunds WJ, Nokes DJ. Hepatitis-B virus endemicity: heterogeneity, catastrophic dynamics and control. Nat Med 2001; 7: 619-624.
45. Gail MH, Rosenberg PS, Goedert JJ. Therapy may explain recent deficits in AIDS incidence. J Acquir Immune Defic Syndr 1990; 3: 296-306.
46. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Costs of hepatitis C. Arch Intern Med 2001; 161: 2231-2237.
47. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242.
48. Lamarre D, Anderson PC, Bailey M et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189.